8-K: TriSalus Life Sciences Reports Q2 2026 Results, Maintains Guidance

TriSalus Life Sciences announced Q2 2026 results, with revenue of $11.4 million and maintained full-year guidance of $54-$57 million, despite increased operating losses driven by sales expansion.

Summary

• TriSalus Life Sciences reported Q2 2026 revenue of $11.4 million, a 1.7% increase year-over-year.
• Gross margins improved to 86.8% from 83.9% in Q2 2025, attributed to reduced cost per TriNav unit.
• Operating losses increased to $9.8 million from $7.3 million in Q2 2025, primarily due to higher sales and marketing expenses.
• Net loss available to common stockholders was $9.2 million, compared to $9.0 million in Q2 2025.
• Adjusted EBITDA losses were $7.1 million, an increase from $5.3 million in Q2 2025.
• The company maintained its full-year 2026 revenue guidance of $54 million to $57 million.
• Cash and cash equivalents stood at $46.3 million as of June 30, 2026, following a Q1 equity offering.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report. While revenue shows slight growth and gross margins improved, operating losses and net losses widened due to increased sales and marketing investments. The company maintains its full-year revenue guidance, which is positive, but the increased burn rate warrants attention.

Positives

• Revenue increased by 1.7% year-over-year to $11.4 million in Q2 2026.
• Gross margins improved to 86.8% from 83.9% in the prior year period.
• The company maintained its full-year 2026 revenue guidance of $54 million to $57 million.
• Cash and cash equivalents increased to $46.3 million, providing sufficient runway for expansion and development.
• The Centers for Medicare and Medicaid Services (CMS) established a G-code for vascular embolization procedures, potentially improving reimbursement.

Negatives

• Operating losses widened to $9.8 million from $7.3 million in the prior year quarter.
• Net loss available to common stockholders increased to $9.2 million from $9.0 million.
• Adjusted EBITDA losses increased to $7.1 million from $5.3 million.
• Increased sales and marketing expenses are impacting profitability in the short term.

Risks

• Future clinical results may not be consistent with patient data generated during clinical trials.
• The cost and timing of all development activities and clinical trials are subject to uncertainty.
• Unexpected safety and efficacy data may be observed during clinical studies.
• The company may continue to raise capital through equity offerings, potentially diluting existing shareholders.
• The company may not be able to achieve applicable revenue requirements to access additional financing under its credit facility.
• The company may not become profitable on its expected timeline, if at all.
• Reported financial results could differ from estimates.
• Changes in competition, market conditions, or the regulatory environment pose risks.

Future Outlook

The company is maintaining its full-year 2026 revenue guidance of $54 million to $57 million, representing 19% to 26% growth compared to 2025. Management anticipates further growth in the second half of the year as sales efforts ramp up.

Management Comments

• "We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our foundation to drive future expansion and adoption of the TriNav platform, and generated clinical evidence that demonstrates and validates the value of our technology."
• "We also wanted to acknowledge the Centers for Medicare and Medicaid Services ("CMS") on the recent establishment of a G-code that extends reimbursement for vascular embolization procedures with the use of a pressure-generating catheter into the physician office-based lab site of service. We look forward to maintaining an active dialogue with CMS as their team finalizes the reimbursement rate in the coming months."
• "We anticipate seeing further growth in the back half of the year and beyond as our sales team continues to ramp their efforts. We believe the long term growth opportunity for our PEDD platform remains substantial, and see an exciting pathway ahead."

Industry Context

StockSavvy.ai notes that TriSalus operates in the competitive oncology market, focusing on novel drug delivery systems and immunotherapies. The recent establishment of a G-code by CMS for vascular embolization procedures is a significant positive development for companies in this space, potentially improving access and reimbursement for treatments utilizing such technologies.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitors were provided in the filing.
• The company's revenue growth of 1.7% year-over-year is modest, while operating losses increased, which is not uncommon for companies investing heavily in sales and marketing for new technologies.

Stakeholder Impact

• Shareholders: Potential for dilution if future capital raises occur; maintained guidance may provide some confidence.
• Employees: Increased sales and marketing investment may lead to team expansion and growth opportunities.
• Customers (Healthcare Providers): Potential for improved reimbursement for procedures using the TriNav system due to the new G-code.
• Creditors: The company's cash position appears sufficient for near-term operations, reducing immediate credit risk.

Next Steps

• Continue to strengthen the foundation for future expansion and adoption of the TriNav platform.
• Generate further clinical evidence validating the technology's value.
• Maintain dialogue with CMS regarding the finalization of reimbursement rates for the new G-code.
• Anticipate further growth in the back half of the year as the sales team ramps up efforts.
• Explore partnership opportunities for the development of nelitolimod.
• Begin exploring partnership opportunities for development of nelitolimod.

Key Dates

Recommendation

The company shows modest revenue growth and improved gross margins, but operating losses are widening due to strategic investments. While maintaining guidance and the positive development of a new G-code are encouraging, the increased burn rate and ongoing need for capital require a cautious approach. A 'hold' recommendation reflects the balance between growth potential and current financial performance.

Keywords

TriNav, PEDD, oncology, vascular embolization, immunotherapeutic, solid tumors, hepatic arterial infusion, CMS